30 August 2022 – Hilltop Leaf Ltd is pleased to announce that it has successfully completed its first MHRA inspection with no Major or Critical observations following an application for a Manufacturer’s Specials licence in line with The Human Medicines Regulations 2012 (as amended) (SI 2012/1916). The resulting licence will confirm Hilltop Leaf is a functioning GMP* facility (*Good Manufacturing Practice).
Board of Directors comment:
We are delighted to have reached this critical milestone. Once again our teams have worked in cross divisional harmony to ensure our facility, systems and procedures meet the incredibly high quality standards required by the MHRA (Medicines & Healthcare products Agency). Our new licence will enable us to operate commercially to meet clinical patients’ needs. This news goes some way to lending further credibility to our ambitious plans. We greatly appreciate all the support from our shareholders, staff and other stakeholders.
